Silo Pharma closes $4M private placement with warrants that could unlock an additional $7.7M
SILO sits 71% above its 52-week low of $3.315 on elevated volume (1.9× avg).
Summary
Silo Pharma closed a $4 million private placement with warrants that could add $7.7 million more, priced at a premium but highly dilutive. The deal follows a reverse stock split and a proxy to increase authorized shares, highlighting urgent funding needs.
Key Events · Financing and Capital Events · SILO
-
Private Placement Closed
Silo Pharma issued 124,000 shares at $6.452 and pre-funded warrants for 495,965 shares at $6.4519, raising $4 million upfront. Net proceeds after fees are approximately $3.5 million.
-
Warrants Add Potential Dilution
Investors received Series A-3 and A-4 warrants each for 619,965 shares at a $6.21 exercise price, plus placement agent warrants for 46,497 shares at $8.065. If fully exercised, total proceeds could reach $11.7 million but would more than double the outstanding share count.
-
Priced at Premium, But Heavy Overhang
The $6.452 share price represents a 14% premium to the current $5.67 stock price, yet the warrants and recent reverse split context suggest the company needed to offer sweeteners to attract capital.
-
Follows Reverse Split and Proxy for More Shares
This financing comes after a 1-for-15 reverse stock split in June 2026 and a pending shareholder vote to increase authorized shares from 6.67 million to 250 million, indicating ongoing dilution risk.
Analysis · SILO · Life Sciences
Through a private placement of shares and pre-funded warrants, Silo Pharma raised $4 million upfront, with attached warrants offering the potential for another $7.7 million if exercised. The deal was priced at $6.452 per share—a premium to the current $5.67 stock price—but the warrants at a $6.21 exercise price and the placement agent's warrants at $8.065 create significant overhang. Net proceeds of $3.5 million extend the cash runway for a company that recently completed a reverse stock split and is seeking shareholder approval to massively increase authorized shares. The financing is highly dilutive: if all warrants are exercised, the total shares issued could exceed 1.8 million, more than doubling the current outstanding shares. This comes just days after the company filed a proxy to boost authorized shares from 6.67 million to 250 million, signaling ongoing capital needs.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SILO was trading at $5.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $3.32 to $15.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.